Molecular Mechanisms of Noncoding RNA in the Occurrence of Castration-Resistant Prostate Cancer

被引:3
作者
Lin, Yu [1 ]
Tan, Haisong [1 ]
Yu, Guopeng [1 ]
Zhan, Ming [1 ,2 ]
Xu, Bin [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Urol, Sch Med, Shanghai 200011, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Core Lab Med Ctr Clin Res, Dept Mol Diagnost & Endocrinol,Sch Med,State Key L, Shanghai 200011, Peoples R China
基金
中国国家自然科学基金;
关键词
castration-resistant prostate cancer; long non-coding RNAs; micro RNAs; androgen receptor; tumor metabolisms; epigenetic modifications; RECEPTOR SPLICE VARIANTS; ANDROGEN DEPRIVATION THERAPY; CELL-PROLIFERATION; GENE-EXPRESSION; ENZALUTAMIDE RESISTANCE; OVERCOMES ENZALUTAMIDE; PACLITAXEL RESISTANCE; DOCETAXEL RESISTANCE; GLUCOSE-METABOLISM; INCREASED SURVIVAL;
D O I
10.3390/ijms24021305
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although several therapeutic options have been shown to improve survival of most patients with prostate cancer, progression to castration-refractory state continues to present challenges in clinics and scientific research. As a highly heterogeneous disease entity, the mechanisms of castration-resistant prostate cancer (CRPC) are complicated and arise from multiple factors. Among them, noncoding RNAs (ncRNAs), the untranslated part of the human transcriptome, are closely related to almost all biological regulation, including tumor metabolisms, epigenetic modifications and immune escape, which has encouraged scientists to investigate their role in CRPC. In clinical practice, ncRNAs, especially miRNAs and lncRNAs, may function as potential biomarkers for diagnosis and prognosis of CRPC. Therefore, understanding the molecular biology of CRPC will help boost a shift in the treatment of CRPC patients. In this review, we summarize the recent findings of miRNAs and lncRNAs, discuss their potential functional mechanisms and highlight their clinical application prospects in CRPC.
引用
收藏
页数:25
相关论文
共 207 条
[1]   MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth [J].
Aakula, Anna ;
Leivonen, Suvi-Katri ;
Hintsanen, Petteri ;
Aittokallio, Tero ;
Ceder, Yvonne ;
Borresen-Dale, Anne-Lise ;
Perala, Merja ;
Ostling, Paivi ;
Kallioniemi, Olli .
MOLECULAR ONCOLOGY, 2015, 9 (07) :1287-1300
[2]   Androgen receptor function is modulated by the tissue-specific AR45 variant [J].
Ahrens-Fath, I ;
Politz, O ;
Geserick, C ;
Haendler, B .
FEBS JOURNAL, 2005, 272 (01) :74-84
[3]   The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma [J].
Andolfo, Immacolata ;
Liguori, Lucia ;
De Antonellis, Pasqualino ;
Cusanelli, Emilio ;
Marinaro, Federica ;
Pistollato, Francesca ;
Garzia, Livia ;
De Vita, Gennaro ;
Petrosino, Giuseppe ;
Accordi, Benedetta ;
Migliorati, Roberta ;
Basso, Giuseppe ;
Iolascon, Achille ;
Cinalli, Giuseppe ;
Zollo, Massimo .
NEURO-ONCOLOGY, 2012, 14 (05) :596-612
[4]   Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting [J].
Antonarakis, E. S. ;
Armstrong, A. J. ;
Dehm, S. M. ;
Luo, J. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (03) :231-241
[5]   AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].
Antonarakis, Emmanuel S. ;
Lu, Changxue ;
Wang, Hao ;
Luber, Brandon ;
Nakazawa, Mary ;
Roeser, Jeffrey C. ;
Chen, Yan ;
Mohammad, Tabrez A. ;
Chen, Yidong ;
Fedor, Helen L. ;
Lotan, Tamara L. ;
Zheng, Qizhi ;
De Marzo, Angelo M. ;
Isaacs, John T. ;
Isaacs, William B. ;
Nadal, Rosa ;
Paller, Channing J. ;
Denmeade, Samuel R. ;
Carducci, Michael A. ;
Eisenberger, Mario A. ;
Luo, Jun .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038
[6]   Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study [J].
Armstrong, Andrew J. ;
Halabi, Susan ;
Luo, Jun ;
Nanus, David M. ;
Giannakakou, Paraskevi ;
Szmulewitz, Russell Z. ;
Danila, Daniel C. ;
Healy, Patrick ;
Anand, Monika ;
Rothwell, Colin J. ;
Rasmussen, Julia ;
Thornburg, Blair ;
Berry, William R. ;
Wilder, Rhonda S. ;
Lu, Changxue ;
Chen, Yan ;
Silberstein, John L. ;
Kemeny, Gabor ;
Galletti, Giuseppe ;
Somarelli, Jason A. ;
Gupta, Santosh ;
Gregory, Simon G. ;
Scher, Howard I. ;
Dittamore, Ryan ;
Tagawa, Scott T. ;
Antonarakis, Emmanuel S. ;
George, Daniel J. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (13) :1120-+
[7]   Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].
Attard, Gerhardt ;
Reid, Alison H. M. ;
Yap, Timothy A. ;
Raynaud, Florence ;
Dowsett, Mitch ;
Settatree, Sarah ;
Barrett, Mary ;
Parker, Christopher ;
Martins, Vanessa ;
Folkerd, Elizabeth ;
Clark, Jeremy ;
Cooper, Colin S. ;
Kaye, Stan B. ;
Dearnaley, David ;
Lee, Gloria ;
de Bono, Johann S. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571
[8]   Tumour metabolism and its unique properties in prostate adenocarcinoma [J].
Bader, David A. ;
McGuire, Sean E. .
NATURE REVIEWS UROLOGY, 2020, 17 (04) :214-231
[9]   Linc00963 Promote Cell Proliferation and Tumor Growth in Castration-Resistant Prostate Cancer by Modulating miR-655/TRIM24 Axis [J].
Bai, Minghua ;
He, Chenchen ;
Shi, Shengjia ;
Wang, Mincong ;
Ma, Jinlu ;
Yang, Pengtao ;
Dong, Yiping ;
Mou, Xingyi ;
Han, Suxia .
FRONTIERS IN ONCOLOGY, 2021, 11
[10]   Alternative splicing as a regulator of development and tissue identity [J].
Baralle, Francisco E. ;
Giudice, Jimena .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2017, 18 (07) :437-451